abstract: INTRODUCTION: A heterogeneous @entity3 is one of the most severe forms of @entity2 ( @entity2 ). In some cases, besides the standard pharmacotherapy, a new treatment option of @entity3 can be used - bronchoscopic lung volume reduction (BLVR) with the use of intrabronchial valves. OBJECTIVES: To examine the health-related quality of life (HRQoL) of @entity0 with severe @entity3 after intrabronchial valve ( @entity4 ) implantation for the treatment of one lung. MATERIAL AND METHODS: From 2011 to 2013 a single centre prospective observational study was performed. The study assessed the effect of the therapeutic BLVR intervention, measured by St. George Respiratory Questionnaire (SGRQ). A statistical analysis by use of Wilcoxon test for dependent variables was performed. RESULTS: Twenty @entity0 were enrolled to the study (mean age 63    10 years), all ex-smokers with @entity1 exposure 38    11.3 packyears. After 3 months of @entity4 treatment the average SGRQ score improved significantly in total (-12.8; p < 0.001) and in domains and the differences were for: "symptoms" (-8.5; p < 0.001), "activity" (-13.9; p < 0.001) and "influence on life"(-13.5; p < 0.002). CONCLUSIONS: The presented study revealed a significant improvement of the quality in the life measured by SGRQ after @entity4 treatment for heterogeneous @entity3 . For the first time our study showed the significant improvement of all three domains of SGRQ after @entity4 treatment.

title: The influence of lung volume reduction with intrabronchial valves on the quality of life of @entity0 with heterogeneous XXXX - a prospective study.

answer: @entity3


abstract: INTRODUCTION: A heterogeneous @entity3 is one of the most severe forms of @entity2 ( @entity2 ). In some cases, besides the standard pharmacotherapy, a new treatment option of @entity3 can be used - bronchoscopic lung volume reduction (BLVR) with the use of intrabronchial valves. OBJECTIVES: To examine the health-related quality of life (HRQoL) of @entity0 with severe @entity3 after intrabronchial valve ( @entity4 ) implantation for the treatment of one lung. MATERIAL AND METHODS: From 2011 to 2013 a single centre prospective observational study was performed. The study assessed the effect of the therapeutic BLVR intervention, measured by St. George Respiratory Questionnaire (SGRQ). A statistical analysis by use of Wilcoxon test for dependent variables was performed. RESULTS: Twenty @entity0 were enrolled to the study (mean age 63    10 years), all ex-smokers with @entity1 exposure 38    11.3 packyears. After 3 months of @entity4 treatment the average SGRQ score improved significantly in total (-12.8; p < 0.001) and in domains and the differences were for: "symptoms" (-8.5; p < 0.001), "activity" (-13.9; p < 0.001) and "influence on life"(-13.5; p < 0.002). CONCLUSIONS: The presented study revealed a significant improvement of the quality in the life measured by SGRQ after @entity4 treatment for heterogeneous @entity3 . For the first time our study showed the significant improvement of all three domains of SGRQ after @entity4 treatment.

title: The influence of lung volume reduction with intrabronchial valves on the quality of life of XXXX with heterogeneous @entity3 - a prospective study.

answer: @entity0


abstract: @entity3 is taken up by the @entity0 host via the respiratory tract. The polysaccharide capsule is regarded as the pathogenetic principle inhibiting phagocytosis of the fungus by cells of the unspecific host defense. Unspecific opsonization of Cr. n. by early phase proteins causes a rapid and successful elimination in the non-compromised host. In case of non-elimination the presence of Cr. n. capsule antigen in excess results in a downregulation of antibody formation thereby inhibiting specific opsonization. Furthermore the blockade of specific T cells and cytotoxic cells by means of free antigen and/or immunocomplexes causes a downregulation of the cellular immunity: Cr. n. antigens of different character induce T suppressor cells inhibiting cellular immunity via a cascade of effector cells and soluble factors. The @entity2 @entity0 enters @entity4 in a state comparable to a Cr. n.-infected non- @entity2 @entity0 whose cellular immunity is already downregulated by this @entity5 itself. Both phenomena--the @entity5 -induced downregulation of cellular immunity as well as the @entity2 -specific lack of @entity1 helper cells and its consequences--act, therefore, synergistically in the same pathogenetic direction. This explains the fulminant development and sequel of @entity4 typical with @entity2 @entity0 . Most probably each exposition of an @entity2 @entity0 to Cr. n. results in clinically manifest @entity4 . The frequence of @entity4 in @entity2 is, therefore, reflecting the general exposure of @entity0 to Cr. n. in a given region. @entity4 in @entity2 is at least about 1000x more frequent than @entity4 in non- @entity2 individuals.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Pathogenesis, immunobiology and epidemiology of XXXX ].

answer: @entity4


abstract: BACKGROUND: @entity5 (TGA) is the most common @entity7 , with an incidence ranging between 0.2 and 0.4 per 1000 live births. Many @entity0 not treated in the first few months of life may progress with severe @entity3 . Treatment of these @entity0 may include palliative surgery to redirect the flow at the atrial level. OBJECTIVE: Report our institutional experience with the palliative Senning procedure in @entity0 diagnosed with TGA and double outlet right ventricle with severe @entity3 , and to evaluate the early and late clinical progression of the palliative Senning procedure. METHODS: Retrospective study based on the evaluation of medical records in the period of 1991 to 2014. Only @entity0 without an indication for definitive surgical treatment of the @entity7 due to elevated pulmonary pressure were included. RESULTS: After one year of follow-up there was a mean increase in arterial @entity1 saturation from 62.1% to 92.5% and a mean decrease in hematocrit from 49.4% to 36.3%. Lung histological analysis was feasible in 16 @entity0 . In 8 @entity0 , pulmonary biopsy grades 3 and 4 were evidenced. CONCLUSION: The palliative Senning procedure improved arterial @entity1 saturation, reduced @entity6 , and provided a better quality of life for @entity0 with TGA with @entity4 , severe @entity2 , and poor prognosis.

title: Palliative Senning in the Treatment of Congenital Heart Disease with XXXX .

answer: @entity2


abstract: We reviewed the records of all @entity0 with @entity2 ( @entity2 ) in Olmsted County, Minnesota, identified through the comprehensive records-linkage system at the Mayo Clinic, and identified 156 @entity2 @entity0 from 1935 to 1991 who had onset of the disease while residing in Olmsted County (incidence cases). Poisson regression analysis revealed that age, gender, and calendar year were associated with incidence. The annual age- and sex-adjusted incidence rate was 5.1 per 100,000 @entity0 -years from 1985 to 1991. On December 1, 1991, 128 @entity0 with a documented history of @entity2 resided in Olmsted County (prevalence cohort). The age- and sex-adjusted prevalence rate per 100,000 was 115. The average length of follow-up for the incidence cohort was 13.2 years. Life table analysis showed that 39% of the 95 @entity0 with isolated @entity2 in the incidence cohort had progressed to clinically definite @entity1 ( @entity1 ) by 10 years of follow-up, that 49% had by 20 years, 54% by 30 years, and 60% by 40 years. There was no difference in the risk of developing @entity1 between @entity0 and @entity0 . The presence of venous sheathing (p = 0.044) and evidence for recurrent @entity2 (p < 0.0001) were associated with an increased likelihood of developing @entity1 . The estimated 25-year survival rate was 88.3% +/- 5.8% for the incidence cohort with isolated @entity2 , compared with 83.9% for the general US population of similar age and sex.

title: XXXX : a population-based study in Olmsted County, Minnesota.

answer: @entity2


abstract: Lymphscintigraphy using Tc-99m human serum albumin (HSA) was examined in 23 @entity0 with peripheral leg @entity2 . Each was injected intradermally with one mCi in the medial web space bilaterally. Images of the lower pelvis and both thighs were obtained within five minutes after injection using an extralarge field view camera GE 500A with low energy all purpose collimator interfaced with G.E. Star computer. These images were acquired in dynamic byte mode, 128 X 128 matrix size, every minute for 40 minutes. Delayed images for this region and of both legs were also taken at 90 minutes and time activity curves from comparable regions of interest over the inguinal area bilaterally were generated. Three patterns emerged: 1--normal lymph flow (12 @entity0 ) characterized by symmetrical or nearly symmetrical early appearance of lymphatics (medial bands) with visualization of inguinal and pelvic lymph nodes in both early and delayed images. Time activity curves showed step ladder rise, in "pulses" every three to four minutes. 2--enhanced lymph flow pattern (6 @entity0 ) was characterized by rapid movement of radiolabelled albumin through dilated lymphatics, occasionally with subcutaneous pooling, and both larger and more numerous inguinal and pelvic nodes on the lymphedematous side. 3--obstructed lymph flow (5 @entity0 ) was characterized by subcutaneous pooling, absent lymphatics, (medial bands) and flat, time activity curve on the lymphedematous side (only background activity) and absent inguinal and pelvic nodes. On delayed images, where @entity1 was incomplete there was delayed appearance of inguinal pelvic nodes which were fewer and smaller compared to the nonedematous side.(ABSTRACT TRUNCATED AT 250 WORDS)

title: Lymphscintigraphy in peripheral XXXX using technetium-labelled human serum albumin: normal and abnormal patterns.

answer: @entity2


abstract: The studied material comprised 15 @entity0 with 12 of them having the episodic from of @entity1 and 3 with chronic form. In the episodic form the age of the @entity0 was from 32 to 48 years, mean age 38. The history of the disease was from 6 to 12 years, the duration of a spell of headaches was 2-3 months and the @entity0 had then 2-5 @entity3 of @entity2 daily. Before the onset of treatment the @entity0 were not given for 1 week any drugs or placebo. After determination of the index of @entity3 treatment was begun. For 7-10 days the @entity0 received daily intramuscular @entity4 25 mg, and then 10 mg for a similar time period. Before the treatment the index of @entity3 was 3.66 (with the total number of @entity3 308). In the first week of treatment it decreased to 1.11 (94 @entity3 ), in the second week it was 0.16 and in the third week 0.05. In 10 @entity0 the @entity3 disappeared completely (83%), in the remaining 2 ones they regressed in a later time. Three @entity0 with the chronic form received this treatment without effect.

title: [Treatment of XXXX with testosterone].

answer: @entity1


abstract: A group of 33 @entity0 with 34 @entity2 and its branches are reported. They were treated in the Department of Neurosurgery, Medical Academy in Warsaw in the years 1965-1981. In 4 @entity0 coexistence of other @entity4 ( @entity3 of other location and/or @entity5 ) was demonstrated. The group comprised 21 @entity0 and 12 @entity0 aged from 7 to 60 years. Nine @entity0 were not operated on, 8 of them died due to haemorrhagic @entity1 and one gave no consent to operation. Out of surgically treated 24 @entity0 in 3 cases the common carotid artery was ligated in 4 cases the wall of the @entity3 was reinforced with plastic mass, and in 17 cases the neck of the @entity3 was closed with a clip. In the clinical group I (Botterell's scale) 7 @entity0 were treated surgically, in group II - 5, in group III - 9 and in group IV - 3. The immediate operative mortality was 8.5% (2 @entity0 ). One @entity0 died 2 months after the operation from other disease. Deterioration of the neurological status occurred in 33% of cases (8 @entity0 ). Late result of the treatment was known in 16 cases with a mean follow-up of 4 years. Six @entity0 returned to work, five resumed work with restrictions, and five other could not work and required care. The results of surgical treatment depended, in the first place, on the clinical state of the @entity0 and the surgical risk was not greater than in cases of @entity3 of other location.

title: [ XXXX and its branches].

answer: @entity2


abstract: Forty-nine cases of @entity4 were evaluated histopathologically and the radiation responses of the @entity0 types were assessed. The overall radiation response were as follows: CR 40.8%, PR 14.3%, NC 42.9%, @entity3 2.0%. The distribution of @entity0 types were: @entity2 (WHO type I) 4.08%; @entity1 (WHO type II) 4.08%; @entity1 (WHO type III) 91.84% var. Lympho-epitheliomatous (LE), Anaplastic (A), Spindle cell (SC), Clear cell (CC). 94.38% of the cases were classified as clinical stage II, III and IV ( @entity0 found beyond the nasopharyngeal space). The radiation response rate of the @entity0 in the lymphnode was reversed to the clinical stage and extent of node involvement, namely the higher stage and node involvement, the less rate of radiation response. Twelve cases received radiation dose of less than 4000 cGy, which comprised 11 NC cases and 1 @entity3 case. Of the 37 cases who got 4000 cGy and over, the response rate was 72.97%. Of these WHO type I was not evaluated because of insufficient radiation dose; WHO type II showed 50% response rate; WHO type III showed 74.29% response rate. Radiation response (as assessed from the cervical lymphnode involvement) of @entity4 was influenced by @entity0 burden and histologic type of the @entity0 , namely the less differentiated @entity0 responded better than the more differentiated one. No definite conclusion can be drawn yet of the different behaviour (if any) of the variants of undifferentiated @entity1 (WHO type III) toward irradiation.

title: XXXX : correlation of histopathology with radiation response.

answer: @entity1


abstract: BACKGROUND: In addition to ultrasound, magnetic resonance imaging (MRI) is considered a suitable, non-invasive technique to assess the type and extent of @entity2 . The distinction between low- and high-flow lesions is crucial because it determines appropriate @entity0 treatment. PURPOSE: To distinguish high-flow from low-flow lesions on the basis of the enhancement pattern on MIP images acquired from dynamic time-resolved MR angiography (MRA) and compare it with previously described MR-based methods. MATERIAL AND METHODS: We examined 25 consecutive @entity0 with previously diagnosed @entity2 . Next, each @entity1 was classified as "high-flow" or "low-flow" using the following criteria: (i) findings on T1-weighted (T1W) and T2-weighted (T2W) imaging (signal voids, signal intensity); (ii) the time interval between the start of arterial enhancement and the onset of lesion enhancement (artery-lesion time); (iii) the time of maximum lesion enhancement; and (iv) analysis of the slope of the enhancement curve. RESULTS: Of the 25 @entity0 , seven had high-flow and 18 had @entity1 . Signal voids on spin-echo T1W images were observed only in four of seven high-flow @entity1 and in two of 18 @entity1 . Analysis of signal intensity on T2W images showed increased signal intensity in 17 of 18 @entity1 , and in two of seven high-flow lesions. Calculation of the artery-lesion time, maximum enhancement time, and slope revealed significant differences between the high- and low-flow groups. CONCLUSION: In conclusion, the slope of the enhancement curve appears to be useful in distinguishing between high- and low-flow @entity2 . Standardization of MR image evaluation criteria is essential.

title: Distinguishing high-flow from low-flow XXXX using maximum intensity projection images in dynamic magnetic resonance angiography - comparison to other MR-based techniques.

answer: @entity2


abstract: A series of 132 consecutive @entity0 with @entity7 of the abdominal aorta or iliac arteries treated between 1979 and 1984 is retrospectively reviewed. 13% had a known @entity5 before @entity4 . Workup consisted of clinical assessment alone in 69%, assisted by ultrasound in 23%. Perioperative mortality was 35% (70%-confidence limits (CL) 30%-39%). Preoperative factors associated with increased mortality were age over 80 years, shock and evidence of @entity6 . In addition, intraoperative blood transfusion over 10 liters, suprarenal site of @entity4 , presence of free intraperitoneal blood, suprarenal aortic clamping and operation lasting longer than 3.5 hours were related to @entity3 , though higher mortality was statistically significant only for operating time and site of clamping. Cardiac morbidity was the most common and most critical factor affecting 52% of @entity0 with a mortality of 59% (CL: 52%-65%). Development of @entity1 in postoperative course was almost uniformly associated with @entity3 (91%, CL: 83%-96%) even with use of dialysis, usually from multiple systems failure. Actuarial five-year survival, including perioperative mortality, was 38% (CL: 33%-43%). After a mean follow up of 3.3 years 82% (CL: 76%-87%) of surviving @entity0 are in good health comparable to the pre- @entity4 state. Although many risk factors exist there are few contraindications to surgery, and results can be improved if workup and operation are rapid and simple. Minimizing @entity2 is essential, while supportive measures in postoperative multiple systems failure still remain a serious problem. Prevention of @entity4 by resection of the intact @entity5 remains the ultimate goal.

title: [ XXXX of the abdominal aorta and iliac arteries. An analysis of 132 cases].

answer: @entity7


abstract: OBJECTIVES: To characterize a radiogenomic risk score (RRS), a previously defined biomarker, and to evaluate its potential for stratifying radiological progression-free survival (rPFS) in @entity0 with @entity1 ( @entity1 ) undergoing pre-surgical treatment with bevacizumab. METHODOLOGY: In this IRB-approved study, prospective imaging analysis of the RRS was performed on phase II clinical trial data of @entity1 @entity0 (n   =   41) evaluating whether @entity0 stratification according to the RRS resulted in groups more or less likely to have a rPFS to pre-surgical bevacizumab prior to cytoreductive nephrectomy. Survival times of RRS subgroups were analyzed using Kaplan-Meier survival analysis. RESULTS: The RRS is enriched in diverse molecular processes including drug response, stress response, protein kinase regulation, and signal transduction pathways (P   <   0.05). The RRS successfully stratified rPFS to bevacizumab based on pre-treatment computed tomography imaging with a median progression-free survival of 6 versus >25  months (P   =   0.005) and overall survival of 25 versus >37  months in the high and low RRS groups (P   =   0.03), respectively. Conventional prognostic predictors including the Motzer and Heng criteria were not predictive in this cohort (P   >   0.05). CONCLUSIONS: The RRS stratifies rPFS to bevacizumab in @entity0 from a phase II clinical trial with @entity1 undergoing cytoreductive nephrectomy and pre-surgical bevacizumab. KEY POINTS:     The RRS SOMA stratifies @entity0 outcomes in a phase II clinical trial.     RRS stratifies subjects into prognostic groups in a discrete or continuous fashion.     RRS is biologically enriched in diverse processes including drug response programs.

title: The radiogenomic risk score stratifies outcomes in a XXXX phase 2 clinical trial.

answer: @entity1


abstract: BACKGROUND: @entity12 remains a significant cause of neonatal and childhood morbidity and mortality in many countries of the world, particularly in developing countries. In some instances, @entity0 recover but remain impaired as a result of @entity1 such as @entity8 , @entity6 and @entity3 . OBJECTIVES: To assess the effectiveness and safety of adjunctive @entity7 in reducing @entity4 and @entity1 in neonates with @entity12 . SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 7), MEDLINE via PubMed (1966 to July 2015), African Index Medicus (up to January 2015), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (up to July 2015), EMBASE (up to July 2015) and the metaRegister of Controlled Trials (mRCT) for ongoing trials. SELECTION CRITERIA: All randomised controlled trials (RCTs) or quasi-RCTs of adjunctive @entity7 for treatment of neonates with @entity12 . DATA COLLECTION AND ANALYSIS: Two review authors independently assessed and extracted data on methods, @entity0 , interventions and outcomes (all-cause @entity4 until hospital discharge, presence of @entity11 at one year and presence of @entity2 or @entity6 at two years, adverse events). Risk ratio (RR), risk difference (RD) and number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) were calculated when appropriate. We assessed quality using the Cochrane risk of bias assessment tool and the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system. MAIN RESULTS: We found two trials with 132 @entity0 that met our inclusion criteria. One of the included trials was a quasi-randomised trial.Adjunctive @entity7 reduced the risk of @entity4 (typical RR 0.46, 95% confidence interval (CI) 0.24 to 0.88; typical RD -0.19, 95% CI -0.33 to -0.04; NNTB = 6; two studies, 132 @entity0 , very low-quality evidence) but did not have a significant effect on the number of @entity0 with @entity11 at two years (RR 1.80, 95% CI 0.18 to 18.21; RD 0.04, 95% CI -0.12 to 0.21; one study, 38 @entity0 , low-quality evidence). In one trial, @entity9 reduced the likelihood of @entity8 at four to 10 weeks post discharge (RR 0.41, 95% CI 0.17 to 0.98; RD -0.25, 95% CI -0.48 to -0.01; one study, 59 @entity0 , low-quality evidence). Data reported on the other outcomes of interest were insufficient. AUTHORS' CONCLUSIONS: Very low-quality data from two randomised controlled trials suggest that some reduction in @entity4 and @entity8 may result from use of adjunctive @entity5 alongside standard antibiotic therapy for treatment of @entity0 with @entity10 . Benefit is not yet seen with regards to reduction in @entity1 . Researchers who wish to clarify these findings must conduct more robustly designed trials with greater numbers of @entity0 , evaluating more relevant outcomes and providing adequate follow-up.

title: Adjuvant @entity7 for reducing XXXX in neonatal @entity12 .

answer: @entity4


abstract: BACKGROUND: @entity12 remains a significant cause of neonatal and childhood morbidity and mortality in many countries of the world, particularly in developing countries. In some instances, @entity0 recover but remain impaired as a result of @entity1 such as @entity8 , @entity6 and @entity3 . OBJECTIVES: To assess the effectiveness and safety of adjunctive @entity7 in reducing @entity4 and @entity1 in neonates with @entity12 . SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 7), MEDLINE via PubMed (1966 to July 2015), African Index Medicus (up to January 2015), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (up to July 2015), EMBASE (up to July 2015) and the metaRegister of Controlled Trials (mRCT) for ongoing trials. SELECTION CRITERIA: All randomised controlled trials (RCTs) or quasi-RCTs of adjunctive @entity7 for treatment of neonates with @entity12 . DATA COLLECTION AND ANALYSIS: Two review authors independently assessed and extracted data on methods, @entity0 , interventions and outcomes (all-cause @entity4 until hospital discharge, presence of @entity11 at one year and presence of @entity2 or @entity6 at two years, adverse events). Risk ratio (RR), risk difference (RD) and number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) were calculated when appropriate. We assessed quality using the Cochrane risk of bias assessment tool and the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system. MAIN RESULTS: We found two trials with 132 @entity0 that met our inclusion criteria. One of the included trials was a quasi-randomised trial.Adjunctive @entity7 reduced the risk of @entity4 (typical RR 0.46, 95% confidence interval (CI) 0.24 to 0.88; typical RD -0.19, 95% CI -0.33 to -0.04; NNTB = 6; two studies, 132 @entity0 , very low-quality evidence) but did not have a significant effect on the number of @entity0 with @entity11 at two years (RR 1.80, 95% CI 0.18 to 18.21; RD 0.04, 95% CI -0.12 to 0.21; one study, 38 @entity0 , low-quality evidence). In one trial, @entity9 reduced the likelihood of @entity8 at four to 10 weeks post discharge (RR 0.41, 95% CI 0.17 to 0.98; RD -0.25, 95% CI -0.48 to -0.01; one study, 59 @entity0 , low-quality evidence). Data reported on the other outcomes of interest were insufficient. AUTHORS' CONCLUSIONS: Very low-quality data from two randomised controlled trials suggest that some reduction in @entity4 and @entity8 may result from use of adjunctive @entity5 alongside standard antibiotic therapy for treatment of @entity0 with @entity10 . Benefit is not yet seen with regards to reduction in @entity1 . Researchers who wish to clarify these findings must conduct more robustly designed trials with greater numbers of @entity0 , evaluating more relevant outcomes and providing adequate follow-up.

title: Adjuvant XXXX for reducing @entity4 in neonatal @entity12 .

answer: @entity7


abstract: BACKGROUND: @entity12 remains a significant cause of neonatal and childhood morbidity and mortality in many countries of the world, particularly in developing countries. In some instances, @entity0 recover but remain impaired as a result of @entity1 such as @entity8 , @entity6 and @entity3 . OBJECTIVES: To assess the effectiveness and safety of adjunctive @entity7 in reducing @entity4 and @entity1 in neonates with @entity12 . SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL; 2015, Issue 7), MEDLINE via PubMed (1966 to July 2015), African Index Medicus (up to January 2015), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (up to July 2015), EMBASE (up to July 2015) and the metaRegister of Controlled Trials (mRCT) for ongoing trials. SELECTION CRITERIA: All randomised controlled trials (RCTs) or quasi-RCTs of adjunctive @entity7 for treatment of neonates with @entity12 . DATA COLLECTION AND ANALYSIS: Two review authors independently assessed and extracted data on methods, @entity0 , interventions and outcomes (all-cause @entity4 until hospital discharge, presence of @entity11 at one year and presence of @entity2 or @entity6 at two years, adverse events). Risk ratio (RR), risk difference (RD) and number needed to treat for an additional beneficial outcome (NNTB) or number needed to treat for an additional harmful outcome (NNTH) were calculated when appropriate. We assessed quality using the Cochrane risk of bias assessment tool and the GRADE (Grades of Recommendation, Assessment, Development and Evaluation) system. MAIN RESULTS: We found two trials with 132 @entity0 that met our inclusion criteria. One of the included trials was a quasi-randomised trial.Adjunctive @entity7 reduced the risk of @entity4 (typical RR 0.46, 95% confidence interval (CI) 0.24 to 0.88; typical RD -0.19, 95% CI -0.33 to -0.04; NNTB = 6; two studies, 132 @entity0 , very low-quality evidence) but did not have a significant effect on the number of @entity0 with @entity11 at two years (RR 1.80, 95% CI 0.18 to 18.21; RD 0.04, 95% CI -0.12 to 0.21; one study, 38 @entity0 , low-quality evidence). In one trial, @entity9 reduced the likelihood of @entity8 at four to 10 weeks post discharge (RR 0.41, 95% CI 0.17 to 0.98; RD -0.25, 95% CI -0.48 to -0.01; one study, 59 @entity0 , low-quality evidence). Data reported on the other outcomes of interest were insufficient. AUTHORS' CONCLUSIONS: Very low-quality data from two randomised controlled trials suggest that some reduction in @entity4 and @entity8 may result from use of adjunctive @entity5 alongside standard antibiotic therapy for treatment of @entity0 with @entity10 . Benefit is not yet seen with regards to reduction in @entity1 . Researchers who wish to clarify these findings must conduct more robustly designed trials with greater numbers of @entity0 , evaluating more relevant outcomes and providing adequate follow-up.

title: Adjuvant @entity7 for reducing @entity4 in neonatal XXXX .

answer: @entity12


abstract: UNASSIGNED: @entity6 venom (BV) has been used as a traditional medicine to treat @entity3 , @entity4 , back @entity1 , @entity0 , and @entity2 . However, the effects of BV on the @entity5 and their action mechanisms have not been reported yet. We used cell viability assay and soft agar colony formation assay for testing cell viability, electro mobility shift assay for detecting DNA binding activity of nuclear factor kappa B (NF-kB) and Western blotting assay for detection of apoptosis regulatory proteins. We found that BV inhibited growth of @entity5 cells through induction of apoptosis. We also found that the expression of death receptor (DR) 4, DR5, p53, p21, Bax, cleaved caspase-3, cleaved caspase-8, and cleaved caspase-9 was increased by BV treatment in a dose dependent manner (0-5  g/ml). Consistent with @entity0 cell growth inhibition, the DNA binding activity of nuclear factor kappa B (NF-kB) was also inhibited by BV treatment. Besides, we found that BV blocked NF-kB activation by directly binding to NF-kB @entity7 subunit. Moreover, combination treatment with BV and @entity7 siRNA or NF-kB inhibitor augmented BV-induced cell growth inhibition. However, @entity7 mutant plasmid ( @entity8 ) transfection partially abolished BV-induced cell growth inhibiton. In addition, BV significantly suppressed @entity0 growth in vivo. Therefore, these results suggested that BV could inhibit @entity5 cell growth, and these anti-proliferative effects may be related to the induction of apoptosis by activation of DR4 and DR5 and inhibition of NF-kB.

title: Anti- @entity0 effect of @entity6 venom on XXXX cell growth by activation of death receptors and inhibition of nuclear factor kappa B.

answer: @entity5


abstract: UNASSIGNED: @entity6 venom (BV) has been used as a traditional medicine to treat @entity3 , @entity4 , back @entity1 , @entity0 , and @entity2 . However, the effects of BV on the @entity5 and their action mechanisms have not been reported yet. We used cell viability assay and soft agar colony formation assay for testing cell viability, electro mobility shift assay for detecting DNA binding activity of nuclear factor kappa B (NF-kB) and Western blotting assay for detection of apoptosis regulatory proteins. We found that BV inhibited growth of @entity5 cells through induction of apoptosis. We also found that the expression of death receptor (DR) 4, DR5, p53, p21, Bax, cleaved caspase-3, cleaved caspase-8, and cleaved caspase-9 was increased by BV treatment in a dose dependent manner (0-5  g/ml). Consistent with @entity0 cell growth inhibition, the DNA binding activity of nuclear factor kappa B (NF-kB) was also inhibited by BV treatment. Besides, we found that BV blocked NF-kB activation by directly binding to NF-kB @entity7 subunit. Moreover, combination treatment with BV and @entity7 siRNA or NF-kB inhibitor augmented BV-induced cell growth inhibition. However, @entity7 mutant plasmid ( @entity8 ) transfection partially abolished BV-induced cell growth inhibiton. In addition, BV significantly suppressed @entity0 growth in vivo. Therefore, these results suggested that BV could inhibit @entity5 cell growth, and these anti-proliferative effects may be related to the induction of apoptosis by activation of DR4 and DR5 and inhibition of NF-kB.

title: Anti- @entity0 effect of XXXX venom on @entity5 cell growth by activation of death receptors and inhibition of nuclear factor kappa B.

answer: @entity6


abstract: UNASSIGNED: @entity6 venom (BV) has been used as a traditional medicine to treat @entity3 , @entity4 , back @entity1 , @entity0 , and @entity2 . However, the effects of BV on the @entity5 and their action mechanisms have not been reported yet. We used cell viability assay and soft agar colony formation assay for testing cell viability, electro mobility shift assay for detecting DNA binding activity of nuclear factor kappa B (NF-kB) and Western blotting assay for detection of apoptosis regulatory proteins. We found that BV inhibited growth of @entity5 cells through induction of apoptosis. We also found that the expression of death receptor (DR) 4, DR5, p53, p21, Bax, cleaved caspase-3, cleaved caspase-8, and cleaved caspase-9 was increased by BV treatment in a dose dependent manner (0-5  g/ml). Consistent with @entity0 cell growth inhibition, the DNA binding activity of nuclear factor kappa B (NF-kB) was also inhibited by BV treatment. Besides, we found that BV blocked NF-kB activation by directly binding to NF-kB @entity7 subunit. Moreover, combination treatment with BV and @entity7 siRNA or NF-kB inhibitor augmented BV-induced cell growth inhibition. However, @entity7 mutant plasmid ( @entity8 ) transfection partially abolished BV-induced cell growth inhibiton. In addition, BV significantly suppressed @entity0 growth in vivo. Therefore, these results suggested that BV could inhibit @entity5 cell growth, and these anti-proliferative effects may be related to the induction of apoptosis by activation of DR4 and DR5 and inhibition of NF-kB.

title: Anti- XXXX effect of @entity6 venom on @entity5 cell growth by activation of death receptors and inhibition of nuclear factor kappa B.

answer: @entity0


abstract: @entity2 during pregnancy and in the puerperium is an uncommon complication, although cases are probably underreported. Fortunately, the mortality rate has improved over the decades. Overall, it was greater than 60% in 1900. By the 1930s, maternal mortality had dropped to 21% and fetal mortality decreased to 50%. Modern rates of maternal mortality have shown continued improvement, with Goldthorp reporting an incidence of 12% in 1966. Over the last 30 years the maternal mortality rate has decreased to approximately 6%, as noted in various series published in the English literature. Fetal mortality rates, however, have remained significantly high. They have remained constant at between 20% and 26%. Furthermore, only one third of @entity0 with prenatal @entity3 complete term pregnancies after operative resolution of their obstruction. These findings emphasize the importance of remembering that two @entity0 are at risk when @entity2 complicates pregnancy. The delay from presentation to admission and from admission to definitive management continues to be a significant cause of morbidity and mortality. A high index of suspicion is mandated in this @entity0 population, especially in those @entity0 presenting with a history of previous abdominal or pelvic surgery. The high incidence of @entity1 bowel found in this subset of @entity0 demonstrates the need for aggressive surgical intervention. Only through diligent and urgent intervention can the morbidity and mortality be decreased. The diagnosis and treatment of a pregnant @entity0 suspected of having a @entity3 should be no different from those given to a nonpregnant one.

title: XXXX in pregnancy.

answer: @entity3


abstract: Measurements of @entity1 (CO) and @entity3 ( @entity2 ) were made in three kitchens, two with gas cookers and one all electric, and two living rooms, one heated by a portable butane heater and the other by a paraffin stove. The measurements were taken whilst the homes were in normal use and the occupants kept a diary of when specific appliances were used. Measurements of @entity2 were made simultaneously by chemiluminescence and by diffusion tubes. The accuracy of the diffusion tube measurements relative to the chemiluminescent standard was estimated as +/- 10% and the precision less than or equal to 300 ppb. hr. Results from diffusion tubes were used to indicate the distribution of @entity2 throughout other rooms in the house. At the all electric house the CO and @entity2 concentrations were very similar to the expected outdoor levels. In all the other houses @entity2 levels exceeded typical outdoor concentrations measured in Central London and in the paraffin heated house and one gas cooking house median CO concentrations exceeded these measured at the curbside of a very busy road in Central London. The living room concentrations of @entity2 where the @entity0 heater was in use were elevated for long periods. Analysis of the decay of pollutant concentration in one kitchen yielded an effective deposition velocity for @entity2 of 3 X 10(-5) m s-1. The magnitude of the CO and @entity2 concentrations measured in this survey confirms that indoor air pollution should be taken into account when assessing overall public exposure to air pollution.

title: Measurements of @entity1 and XXXX in British homes using unflued heating or cooking appliances.

answer: @entity3


abstract: Measurements of @entity1 (CO) and @entity3 ( @entity2 ) were made in three kitchens, two with gas cookers and one all electric, and two living rooms, one heated by a portable butane heater and the other by a paraffin stove. The measurements were taken whilst the homes were in normal use and the occupants kept a diary of when specific appliances were used. Measurements of @entity2 were made simultaneously by chemiluminescence and by diffusion tubes. The accuracy of the diffusion tube measurements relative to the chemiluminescent standard was estimated as +/- 10% and the precision less than or equal to 300 ppb. hr. Results from diffusion tubes were used to indicate the distribution of @entity2 throughout other rooms in the house. At the all electric house the CO and @entity2 concentrations were very similar to the expected outdoor levels. In all the other houses @entity2 levels exceeded typical outdoor concentrations measured in Central London and in the paraffin heated house and one gas cooking house median CO concentrations exceeded these measured at the curbside of a very busy road in Central London. The living room concentrations of @entity2 where the @entity0 heater was in use were elevated for long periods. Analysis of the decay of pollutant concentration in one kitchen yielded an effective deposition velocity for @entity2 of 3 X 10(-5) m s-1. The magnitude of the CO and @entity2 concentrations measured in this survey confirms that indoor air pollution should be taken into account when assessing overall public exposure to air pollution.

title: Measurements of XXXX and @entity3 in British homes using unflued heating or cooking appliances.

answer: @entity1


abstract: @entity7 inhibitors induce an increase in kinin levels with subsequent release of @entity5 (NO) and @entity11 , as shown in cultured endothelial cells and isolated @entity0 hearts. Isolated perfused working @entity0 hearts continuously release kinins and @entity11 . During @entity1 after ligation of the left coronary artery kinin and @entity11 concentrations in the venous effluent of the hearts are increased. @entity7 inhibition with ramiprilat increases kinin concentrations during normoxia, @entity1 and reperfusion, whereas deendothelialization markedly reduces kinin and @entity11 outflow in controls as well as in @entity7 inhibitor-treated hearts. @entity0 hearts with postischemic reperfusion @entity6 are protected by ramiprilat- and @entity8 perfusion, cardiodynamics and metabolism of treated hearts are improved. These effects are observed in concentrations too low to increase coronary flow. The cardioprotective effects of ramiprilat and @entity8 are abolished by the specific B2-kinin receptor antagonist icatibant and by an inhibitor of NO-synthase. Long-term treatment (20 weeks) with @entity9 in a blood-pressure-lowering dose (1 mg/kg/day) and a subantihypertensive dose (10 micromg/kg/day) protects spontaneously @entity3 @entity0 ( @entity2 prone) against @entity3 and @entity10 in the high dose. In addition, both treatment regimens induce myocardial capillary growth. Isolated hearts of these animals show @entity4 and coronary flow, reduced release of cytosolic enzymes into the coronary effluent, and improved myocardial metabolism. These changes are observed even at a dose of @entity9 which does not affect blood pressure and @entity10 . They are abolished by chronic blockade of kinin receptors with icatibant.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Cardioprotective effects by XXXX after @entity1 and reperfusion in animal experiment studies].

answer: @entity9


abstract: @entity7 inhibitors induce an increase in kinin levels with subsequent release of @entity5 (NO) and @entity11 , as shown in cultured endothelial cells and isolated @entity0 hearts. Isolated perfused working @entity0 hearts continuously release kinins and @entity11 . During @entity1 after ligation of the left coronary artery kinin and @entity11 concentrations in the venous effluent of the hearts are increased. @entity7 inhibition with ramiprilat increases kinin concentrations during normoxia, @entity1 and reperfusion, whereas deendothelialization markedly reduces kinin and @entity11 outflow in controls as well as in @entity7 inhibitor-treated hearts. @entity0 hearts with postischemic reperfusion @entity6 are protected by ramiprilat- and @entity8 perfusion, cardiodynamics and metabolism of treated hearts are improved. These effects are observed in concentrations too low to increase coronary flow. The cardioprotective effects of ramiprilat and @entity8 are abolished by the specific B2-kinin receptor antagonist icatibant and by an inhibitor of NO-synthase. Long-term treatment (20 weeks) with @entity9 in a blood-pressure-lowering dose (1 mg/kg/day) and a subantihypertensive dose (10 micromg/kg/day) protects spontaneously @entity3 @entity0 ( @entity2 prone) against @entity3 and @entity10 in the high dose. In addition, both treatment regimens induce myocardial capillary growth. Isolated hearts of these animals show @entity4 and coronary flow, reduced release of cytosolic enzymes into the coronary effluent, and improved myocardial metabolism. These changes are observed even at a dose of @entity9 which does not affect blood pressure and @entity10 . They are abolished by chronic blockade of kinin receptors with icatibant.(ABSTRACT TRUNCATED AT 250 WORDS)

title: [Cardioprotective effects by @entity9 after XXXX and reperfusion in animal experiment studies].

answer: @entity1


abstract: Isolated coronary perfused @entity2 hearts were used to determine if aging alters left ventricular (LV) intrinsic contractile response to unresuscitated @entity3 . We first compared control hearts from both young (N = 10) and aged (N = 10) @entity2 . Compared with young control hearts, aged control hearts showed significantly lower left ventricular performance (LVP) (84.2 +/- 1.6 v 76.0 +/- 1.5; P less than 0.003), +dP/dtmax (1417.5 +/- 52.4 v 1048 +/- 48.7; P less than 0.001), and -dP/dtmax (1079 +/- 79 v 916 +/- 27; P less than 0.001) at a left ventricular end-diastolic pressure (LVEDP) of 10 mmHg. A 43% +/- 2% third-degree burn (Walker model) was studied in 20 young and 10 aged @entity2 . The aged burn hearts showed significantly lower LVP (57.1 +/- 2.1 v 65.5 +/- 2.0; P less than 0.01) and +dP/dtmax (1026 +/- 66.4 v 1219 +/- 59.9; P less than 0.001) at an LVEDP of 10 mm Hg. In addition, LV function curves for the aged burn hearts were shifted downward and to the right of curves obtained from the young burn hearts (P less than 0.05). Contractile defects in the aged group were neither related to altered beating frequency nor to maximally effective increases in diastolic stretch. While increased extracellular @entity1 concentration (from 1 to 8 millimolar [mM]) increased LVP, +dP/dtmax, and -dP/dtmax in a dose-dependent manner in both young and aged burn hearts, absolute values of measured contractile performance were consistently less in the aged hearts compared with the young hearts at identical @entity1 concentrations. Finally, we examined the effects of @entity0 on contractile function within the aged group. Peak LVP and maximal rate of relaxation were uniformly decreased in all burn hearts compared with control aged hearts. The +dP/dtmax was not significantly altered by burn in this age group (burn: 1026 +/- 66; control: 1048 +/- 49). This study suggests that severe myocardial contractile changes resulting from a major thermal insult in subjects with already compromised hearts is likely a significant limiting factor in the response to @entity3 .

title: The effects of aging on the cardiac contractile response to unresuscitated XXXX .

answer: @entity0


abstract: Serum @entity2 ( @entity2 ) determinations were performed every other day during the luteal phase of the menstrual cycle of 20 @entity0 suffering from @entity1 and of 20 @entity0 assumed to be fertile. @entity2 was determined by a specific radioimmunoassay which applied an antiserum directed against the @entity2 -beta subunit. The group of @entity1 @entity0 demonstrated detectable serum @entity2 in only three cases. No clinically confirmed pregnancies were achieved in this group. Eighteen of the 20 @entity0 presumed to be fertile showed detectable @entity2 levels. Five of these achieved ongoing pregnancies, while 13 @entity0 revealed increased @entity2 levels without delayed menstrual periods. The first day of detection of @entity2 during the luteal phase did not differ between the two groups. In the five @entity0 with ongoing pregnancies the time of detection of @entity2 ranged from day 5 until day 12 after ovulation. It is concluded that the high rate of increased @entity2 values in the fertile group may represent early conceptual loss, but the apparently disorderly @entity2 results indicate the need for cautious interpretation of @entity2 determinations during the luteal phase. Furthermore, early conceptual loss forms no major explanation for @entity1 .

title: @entity0 chorionic gonadotrophin measurements in the luteal phase of the menstrual cycle of XXXX and fertile @entity0 .

answer: @entity1


abstract: Serum @entity2 ( @entity2 ) determinations were performed every other day during the luteal phase of the menstrual cycle of 20 @entity0 suffering from @entity1 and of 20 @entity0 assumed to be fertile. @entity2 was determined by a specific radioimmunoassay which applied an antiserum directed against the @entity2 -beta subunit. The group of @entity1 @entity0 demonstrated detectable serum @entity2 in only three cases. No clinically confirmed pregnancies were achieved in this group. Eighteen of the 20 @entity0 presumed to be fertile showed detectable @entity2 levels. Five of these achieved ongoing pregnancies, while 13 @entity0 revealed increased @entity2 levels without delayed menstrual periods. The first day of detection of @entity2 during the luteal phase did not differ between the two groups. In the five @entity0 with ongoing pregnancies the time of detection of @entity2 ranged from day 5 until day 12 after ovulation. It is concluded that the high rate of increased @entity2 values in the fertile group may represent early conceptual loss, but the apparently disorderly @entity2 results indicate the need for cautious interpretation of @entity2 determinations during the luteal phase. Furthermore, early conceptual loss forms no major explanation for @entity1 .

title: XXXX chorionic gonadotrophin measurements in the luteal phase of the menstrual cycle of @entity1 and fertile @entity0 .

answer: @entity0


abstract: Serum @entity2 ( @entity2 ) determinations were performed every other day during the luteal phase of the menstrual cycle of 20 @entity0 suffering from @entity1 and of 20 @entity0 assumed to be fertile. @entity2 was determined by a specific radioimmunoassay which applied an antiserum directed against the @entity2 -beta subunit. The group of @entity1 @entity0 demonstrated detectable serum @entity2 in only three cases. No clinically confirmed pregnancies were achieved in this group. Eighteen of the 20 @entity0 presumed to be fertile showed detectable @entity2 levels. Five of these achieved ongoing pregnancies, while 13 @entity0 revealed increased @entity2 levels without delayed menstrual periods. The first day of detection of @entity2 during the luteal phase did not differ between the two groups. In the five @entity0 with ongoing pregnancies the time of detection of @entity2 ranged from day 5 until day 12 after ovulation. It is concluded that the high rate of increased @entity2 values in the fertile group may represent early conceptual loss, but the apparently disorderly @entity2 results indicate the need for cautious interpretation of @entity2 determinations during the luteal phase. Furthermore, early conceptual loss forms no major explanation for @entity1 .

title: @entity0 chorionic gonadotrophin measurements in the luteal phase of the menstrual cycle of @entity1 and fertile XXXX .

answer: @entity0


abstract: Convenience of medicine-taking and lack of side effects are two major factors that favor compliance. Using a simple and convenient once-a-day regimen of @entity3 , @entity4 , and @entity5 , we treated successfully 30 @entity0 with moderate to severe @entity1 . All @entity0 were previously taking at least three medications, usually three to four times a day. Treatment was started with @entity4 (160 mg) and @entity5 (50 mg) once daily. If diastolic blood pressure remained above 90 mmHg, @entity3 was added at a starting dose of 2.5 mg/day and increased weekly until blood pressure was controlled or the maximum dose of 100 mg/day was reached. The average blood pressure decreased from 170.9/107.0 mmHg (sitting) and 174.1/110.8 mmHg (standing), before the addition of @entity3 , to 138.8/86.7 mmHg (sitting) and 140.0/89.5 mmHg (standing), at the third month of @entity3 therapy. At the sixth month of @entity3 therapy, the figures were 140.9/86.3 and 141.9/89.8 mmHg. With this single-dose program, smooth blood pressure control throughout 24 hours was documented by 24-hour ambulatory blood-pressure monitoring. @entity6 was common but was bothersome only to @entity0 @entity0 . @entity2 occurred in five @entity0 , but they were all small and asymptomatic. Subjective side effects of the regimen were usually so mild that all @entity0 who completed the study decided to remain on the same regimen.

title: XXXX in a once-a-day step-3 antihypertensive program.

answer: @entity3


abstract: CASE STUDYBJ is a 34-year-old @entity1 who was diagnosed with metastatic @entity0 . She was treated with surgical @entity2 and sentinel node biopsy. Following surgery, she received chemotherapy. She was given antiemetic therapy prior to and immediately following chemotherapy. She began to experience significant and persistent @entity5 with intermittent episodes of @entity6 after the second cycle of chemotherapy. She completed her chemotherapy but still experienced @entity5 and @entity6 in response to several cues, such as smelling food cooking and going to the hospital. Her @entity5 and @entity6 resulted in segregation from her family during meal time, which negatively impacted her quality of life. @entity7 was requested, and BJ was cooperative. She reported feeling very nauseated at the time of the interview. Hypnosis was discussed; her questions were answered, and the potential risks and benefits of hypnosis were reviewed. She agreed that she would like to try hypnosis. A hypnosis assessment was conducted and revealed that she had a history of profound motion @entity9 and severe, chronic childhood trauma associated with feelings of @entity3 and hypervigilance. The therapeutic suggestions that were used with BJ included hypnotic suggestions for relaxation and removal of discomfort. A metaphor describing the central processing of the @entity8 as a thermostat that could be adjusted to reduce and eliminate the sensation was used to suggest that she could control her perceptions and in turn control the @entity5 . Posthypnotic suggestions included that at the earliest awareness of discomfort, rubbing the throat would eliminate that discomfort, and @entity10 would be transformed into her favorite fragrance. Reversal went smoothly, and BJ reported satisfaction with the experience. BJ experienced significant @entity4 after the first session. She had two more sessions, at which time she was able to eat with her family and go to the clinic without discomfort. She was provided a CD with a recording of her hypnosis script to reinforce the face-to-face intervention. She continues to be symptom-free 3 months after treatment with hypnosis.

title: Hypnosis for the Management of XXXX .

answer: @entity8


abstract: To evaluate arterial physiopathology, complete arterial wall mechanical characterization is necessary. This study presents a model for determining the elastic response of @entity3 (sigma E, where sigma is stress), collagen (sigma C), and smooth muscle (sigma SM) fibers and viscous (sigma @entity2 ) and inertial (sigma M) aortic wall behaviors. Our work assumes that the total stress developed by the wall to resist stretching is governed by the elastic modulus of @entity3 fibers (EE), the elastic modulus of collagen (EC) affected by the fraction of collagen fibers (fC) recruited to support wall stress, and the elastic modulus of the maximally contracted vascular smooth muscle (ESM) affected by an activation function (fA). We constructed the constitutive equation of the aortic wall on the basis of three different hookean materials and two nonlinear functions, fA and fC: sigma = sigma E + sigma C + sigma SM + sigma @entity2 + sigma M = EE. (epsilon - epsilon 0E) + EC.fC.epsilon + ESM.fA.epsilon + @entity2 . [equation: see text] + M.[equation: see text] where epsilon is strain and epsilon 0E is strain at zero stress. Stress-strain relations in the control state and during activation of smooth muscle ( @entity1 , 5 micrograms.kg-1.min-1 IV) were obtained by transient occlusions of the descending aorta and the inferior vena cava in 15 conscious @entity0 by using descending thoracic aortic pressure (microtransducer) and diameter (sonomicrometry) measurements. The fC was not linear with strain, and at the onset of significant collagen participation in the elastic response (break point of the stress-strain relation), 6.02 +/- 2.6% collagen fibers were recruited at 23% of stretching of the unstressed diameter. The fA exhibited a skewed unimodal curve with a maximum level of activation at 28.3 +/- 7.9% of stretching. The aortic wall dynamic behavior was modified by activation increasing viscous ( @entity2 ) and inertial (M) moduli from the control to active state (viscous, 3.8 +/- 1.3 x 10(4) to 7.8 +/- 1.1 x 10(4) dyne.s.cm-2, P < .0005; inertial, 61 +/- 42 to 91 +/- 23 dyne.s2.cm-2, P < .05). Finally, the purely elastic stress-strain relation was assessed by subtracting the viscous and inertial behaviors.

title: Arterial wall mechanics in conscious XXXX . Assessment of viscous, inertial, and elastic moduli to characterize aortic wall behavior.

answer: @entity0


abstract: INTRODUCTION: In the field of @entity2 prevention, the prophylactic mesh-reinforcement of stoma-sites is one of the most controversially discussed issues. The incidence of @entity2 in the literature reported to be up to 48.1% after end colostomy and up to 30.8% after loop of colostomy, but still remains uncertain due to diagnostic variety of clinical or radiological methods, heterogeneous @entity0 groups and variable follow-up intervals. Anyway, the published data regarding the use of synthetic or bio-prostethic meshes in the prevention of @entity2 at the primary operation are very scarce. METHODS: A literature search of the Medline database in terms of biological prophylactic mesh implantation in stoma creation identified six systematic reviews, two @entity1 ( @entity1 ), two case-controlled studies, and one technical report. RESULTS: In a systematic review focusing on the prevention of @entity2 including only RCTs encompassing one @entity1 using bio-prosthetic mesh the incidence of @entity3 was 12.5% compared to 53% in the control group (p   <   0.0001). In one @entity1 and two case-control studies, respectively, there was a significant smaller incidence of @entity3 as well as a similar complication rate compared to the control group. Only in one @entity1 , no significant difference regarding the incidence of @entity2 was reported with comparable complication rates. CONCLUSION: Thus, so far two @entity1 and two case-control studies are published with prophylactic bio-prosthetic reinforcement in stoma sites. The majority revealed significant better results in terms of @entity3 and without any mesh-related complications in comparison to the non mesh group. Further, multicenter @entity1 are required to achieve a sufficient level of recommendation.

title: Prevention of a XXXX by Biological Mesh Reinforcement.

answer: @entity2


abstract: UNASSIGNED: Introduction. Long-term psychological consequences of @entity5 are receiving more attention in recent years. The aim of our study was to assess the correlation of @entity3 and symptoms of @entity4 ( @entity4 ) @entity1 and @entity2 after ICU-discharge in a Danish cohort. Methods. A prospective observational cohort study assessing the incidence of @entity3 in the ICU. Psychometrics were screened by validated tools in structured telephone interviews after 2 months (n = 297) and 6 months (n = 248) after ICU-discharge. Results. @entity3 was detected in 54% of @entity0 in the ICU and symptoms of @entity4 in 8% (2 months) and 6% (6 months) after ICU-discharge. Recall of ICU stay was present in 93%. Associations between @entity3 and post-discharge @entity4 were weak and insignificant. Memories of delusions were significantly associated with @entity1 after two months. Remaining associations between types of ICU-memories and prevalence of post-discharge symptoms of @entity4 , @entity1 , and @entity2 were insignificant after adjusting for age. Incidence of @entity3 was unaffected by preadmission use of psychotropic drugs. Prevalence of @entity4 was unaffected by use of antipsychotics and sedation in the ICU. Conclusion. @entity3 did not increase the risk of @entity4 and 6 months after ICU discharge.

title: Symptoms of Posttraumatic Stress after Intensive Care XXXX .

answer: @entity3


abstract: BACKGROUND: Cell based vaccines encoding @entity7 ( @entity7 ) and Hyper-IL-11 (H11) present high activity in @entity1 @entity3 and @entity4 model. We evaluated the efficacy of cellular vaccines modified with @entity7 or H11 combined with @entity5 in orthotopic @entity1 @entity2 model. MATERIAL AND METHODS: @entity6 cells were transduced with @entity7 and H11 cDNA ( @entity6 - @entity7 and @entity6 -H11). An orthotopic @entity6 model based on the implantation of @entity6 cells into the dorsolateral lobe of the prostate of C57BL6/J @entity1 was employed. The efficacy of @entity6 - @entity7 and @entity6 -H11 vaccines evaluated in the therapeutic setting was compared with the @entity6 cells modified with a mock transduced E1-deleted adenoviral vector ( @entity6 -AdV) and non-modified irradiated @entity6 cells ( @entity6 IRR) in relation to naive (non-immunized) @entity1 . In the next experimental groups @entity1 vaccinated with @entity6 - @entity7 and @entity6 -H11 received @entity5 (CY). Detection of immune cells in the spleen in @entity1 receiving vaccines combined with CY was evaluated. RESULTS: Modification of @entity6 cells with @entity7 increased the efficacy of @entity6 -based whole-cell vaccine. The highest response rate was observed in @entity1 receiving @entity6 - @entity7 alone and combined with CY. Vaccination with @entity6 - @entity7 alone and combined with CY and @entity6 H11 combined with CY extended median OS of @entity1 bearing orthotopic @entity6 @entity0 in therapeutic setting. Low dose CY administered alone demonstrated some antitumor activity in employed model. @entity6 - @entity7 or @entity6 -H11 combined with CY strongly augmented generation of CD8+, CD4+ T lymphocytes and memory T cells. Immunization with @entity6 combined with or without CY suppressed generation of T regulatory cells. CONSLUSIONS: @entity2 vaccines modified with @entity7 or H11 induce prostate @entity0 regression and increase @entity1 survival by stimulating the immune system. @entity5 added to modified @entity6 vaccines demonstrated clinical benefit of treated @entity1 and enhanced anti- @entity0 immune response.

title: Cell-based Hyper-interleukin 6 or Hyper-interleukin 11 secreting vaccines combined with low dose XXXX in an orthotopic @entity1 @entity2 model.

answer: @entity5


abstract: BACKGROUND: Cell based vaccines encoding @entity7 ( @entity7 ) and Hyper-IL-11 (H11) present high activity in @entity1 @entity3 and @entity4 model. We evaluated the efficacy of cellular vaccines modified with @entity7 or H11 combined with @entity5 in orthotopic @entity1 @entity2 model. MATERIAL AND METHODS: @entity6 cells were transduced with @entity7 and H11 cDNA ( @entity6 - @entity7 and @entity6 -H11). An orthotopic @entity6 model based on the implantation of @entity6 cells into the dorsolateral lobe of the prostate of C57BL6/J @entity1 was employed. The efficacy of @entity6 - @entity7 and @entity6 -H11 vaccines evaluated in the therapeutic setting was compared with the @entity6 cells modified with a mock transduced E1-deleted adenoviral vector ( @entity6 -AdV) and non-modified irradiated @entity6 cells ( @entity6 IRR) in relation to naive (non-immunized) @entity1 . In the next experimental groups @entity1 vaccinated with @entity6 - @entity7 and @entity6 -H11 received @entity5 (CY). Detection of immune cells in the spleen in @entity1 receiving vaccines combined with CY was evaluated. RESULTS: Modification of @entity6 cells with @entity7 increased the efficacy of @entity6 -based whole-cell vaccine. The highest response rate was observed in @entity1 receiving @entity6 - @entity7 alone and combined with CY. Vaccination with @entity6 - @entity7 alone and combined with CY and @entity6 H11 combined with CY extended median OS of @entity1 bearing orthotopic @entity6 @entity0 in therapeutic setting. Low dose CY administered alone demonstrated some antitumor activity in employed model. @entity6 - @entity7 or @entity6 -H11 combined with CY strongly augmented generation of CD8+, CD4+ T lymphocytes and memory T cells. Immunization with @entity6 combined with or without CY suppressed generation of T regulatory cells. CONSLUSIONS: @entity2 vaccines modified with @entity7 or H11 induce prostate @entity0 regression and increase @entity1 survival by stimulating the immune system. @entity5 added to modified @entity6 vaccines demonstrated clinical benefit of treated @entity1 and enhanced anti- @entity0 immune response.

title: Cell-based Hyper-interleukin 6 or Hyper-interleukin 11 secreting vaccines combined with low dose @entity5 in an orthotopic @entity1 XXXX model.

answer: @entity2


abstract: BACKGROUND: Cell based vaccines encoding @entity7 ( @entity7 ) and Hyper-IL-11 (H11) present high activity in @entity1 @entity3 and @entity4 model. We evaluated the efficacy of cellular vaccines modified with @entity7 or H11 combined with @entity5 in orthotopic @entity1 @entity2 model. MATERIAL AND METHODS: @entity6 cells were transduced with @entity7 and H11 cDNA ( @entity6 - @entity7 and @entity6 -H11). An orthotopic @entity6 model based on the implantation of @entity6 cells into the dorsolateral lobe of the prostate of C57BL6/J @entity1 was employed. The efficacy of @entity6 - @entity7 and @entity6 -H11 vaccines evaluated in the therapeutic setting was compared with the @entity6 cells modified with a mock transduced E1-deleted adenoviral vector ( @entity6 -AdV) and non-modified irradiated @entity6 cells ( @entity6 IRR) in relation to naive (non-immunized) @entity1 . In the next experimental groups @entity1 vaccinated with @entity6 - @entity7 and @entity6 -H11 received @entity5 (CY). Detection of immune cells in the spleen in @entity1 receiving vaccines combined with CY was evaluated. RESULTS: Modification of @entity6 cells with @entity7 increased the efficacy of @entity6 -based whole-cell vaccine. The highest response rate was observed in @entity1 receiving @entity6 - @entity7 alone and combined with CY. Vaccination with @entity6 - @entity7 alone and combined with CY and @entity6 H11 combined with CY extended median OS of @entity1 bearing orthotopic @entity6 @entity0 in therapeutic setting. Low dose CY administered alone demonstrated some antitumor activity in employed model. @entity6 - @entity7 or @entity6 -H11 combined with CY strongly augmented generation of CD8+, CD4+ T lymphocytes and memory T cells. Immunization with @entity6 combined with or without CY suppressed generation of T regulatory cells. CONSLUSIONS: @entity2 vaccines modified with @entity7 or H11 induce prostate @entity0 regression and increase @entity1 survival by stimulating the immune system. @entity5 added to modified @entity6 vaccines demonstrated clinical benefit of treated @entity1 and enhanced anti- @entity0 immune response.

title: Cell-based Hyper-interleukin 6 or Hyper-interleukin 11 secreting vaccines combined with low dose @entity5 in an orthotopic XXXX @entity2 model.

answer: @entity1


abstract: Eighteen @entity0 underwent surgery for @entity6 (16 left atrial and 2 right atrial) during the last 10 years. Seventeen @entity0 had @entity1 stalk attached to the oval fossa. The @entity5 was excised along with a cuff of the @entity3 , which was reconstructed using a Dacron patch in 15 @entity0 and by direct suture in 2 @entity0 . In the remaining case the @entity5 was attached to the left atrial wall and adjacent @entity2 . There was only one early death in a @entity0 who underwent a concomitant lobectomy for @entity4 and one late death due to a noncardiac cause. During the follow-up period of 3-96 months (average 36 months) all the survivors were in New York Heart Association Class I. Scanning electron microscopy of @entity1 tissue was done in 8 cases. The morphological findings did not help in categorizing the @entity1 into any pathological subgroups. Postoperative cardiac catheterization done in 3 @entity0 (30-50 months postoperatively) showed return of haemodynamics to normal. Echocardiographic studies done postoperatively have not revealed recurrence of @entity1 in any @entity0 . Surgical excision of @entity5 is possible with very gratifying long-term results.

title: Surgical experience with XXXX .

answer: @entity6


abstract: Eliciting @entity1 during electroconvulsive therapy (ECT) is essential for therapeutic purposes. When it exceeds beyond 120 seconds (Freeman, 1995) i.e., prolonged, it adds to adverse effects of ECT. Estimating @entity1 duration using 'cuff method' alone has limitations. This study examined the merits of electroencephalographic (EEG) monitoring in routine ECT practice on a large representative sample. Modified ECT either unilateral or bilateral electrode placement, was administered to 485 @entity0 under EEG monitoring at first ECT session. Ninety one (18.8%) @entity0 had prolonged @entity1 of which only 59 would have been detected if 'cuff method' alone was used. Twenty nine (6%) @entity0 had inadequate motor @entity1 but had adequate EEG @entity1 duration. Twenty five (5.2%) of them had no motor @entity1 and two such @entity0 even had prolonged @entity1 . The prolonged @entity1 was unpredictable in majority. In conclusion, EEG monitoring during ECT is essential to detect both adequacy of @entity1 in @entity0 having no or inadequate motor @entity1 and a/so to detect prolonged @entity1 .

title: Merits of EEG monitoring during ect: a prospective study on 485 XXXX .

answer: @entity0


abstract: We have utilized a very-low-calorie formula diet (VLCD) along with multidisciplinary group counselling in an attempt to achieve and maintain major @entity5 in 4026 morbidity @entity2 @entity0 . Using a 420-cal protein supplement (Optifast), @entity0 lost weight, at an average of 4.6 +/- 0.9 lb/week and @entity0 , 3.1 +/- 1.1 lb/week. @entity0 remained on the VLCD an average of 13.2 weeks, resulting in a mean @entity5 of 66.0 +/- 8.1 lb; @entity0 remained on the fast an average of 14.1 weeks, with an average loss of 47.3 +/- 4.2 lb. Outcome analysis revealed that 25 percent of @entity0 were unable to adapt to this approach, dropping out within the first 3 weeks. Of the @entity0 remaining in the program, 68 percent lost considerable weight, but did not reach their goal; of this group, recidivism was extremely high, with only 5-10 percent maintaining @entity5 after 18 months. Thirty-two percent of the @entity0 successfully attained goal weight; the holding rate of this group has been considerably greater, with 30 percent of @entity0 and 58 percent of @entity0 maintaining @entity5 (within 10 lbs) for a minimum of 18 months. Complications of @entity2 i.e. @entity3 , @entity1 , and @entity6 were remarkably improved after @entity5 . Complications of the VLCD including @entity4 , were minimal. Our 8-year experience strongly suggests that the VLCD approach using high quality protein supplement and multi-disciplinary counselling provides a reasonable success rate for achieving and maintaining @entity5 in the morbidity @entity2 population.

title: An eight-year experience with a very-low-calorie formula diet for control of major XXXX .

answer: @entity2


abstract: OBJECTIVE: there is a paucity of clinical evidence regarding the amount and frequency of repositioning of pathologically migrated teeth after conventional periodontal treatment. The present study was carried out to find and relate these two parameters of periodontal success with severity of @entity1 . METHOD AND MATERIALS: a total of 45 subjects with a history of recently formed @entity2 or noticeable increase in already existing @entity2 were selected. Twenty-nine @entity0 with 76 @entity2 sites participated in the study (16 @entity0 were lost to follow-up). Repositioning was assessed by measuring the sites on study models obtained at baseline, reevaluation at 6 weeks after nonsurgical periodontal therapy, and 4 months after surgery. RESULTS: after nonsurgical therapy, 65.78% of sites demonstrated some degree of repositioning, while 7.89% closed completely. Four months after surgical treatment, 32.30% of sites showed complete repositioning and 47.69% of sites showed an additional partial repositioning. This corresponds to a 79.99% rate of positive responses to therapy. When sites measuring     1 mm were considered, 65.38% showed complete closure and 96.15% demonstrated positive response to therapy. CONCLUSION: the findings suggest that there is an inverse relationship between the severity of @entity1 and amount (as well as frequency) of repositioning. The results emphasize the importance of early diagnosis in the successful treatment of pathologic @entity1 to prevent more complex and time-consuming orthodontic and prosthodontic procedures.

title: Clinical evaluation of correction of pathologic XXXX with periodontal therapy.

answer: @entity1


abstract: PURPOSE: The authors tried to assess the treatment outcomes depending on the extent of resection in axial @entity2 and compare the outcome of two adjunctive therapies (external beam radiation therapy vs. stereotactic radiosurgery) following incomplete @entity1 resection in terms of @entity1 control. @entity0 AND METHODS: We retrospectively reviewed 30 consecutive @entity0 with @entity2 involving skull base, sacrum and mobile spine between 1993 and 2008. Their initial treatments had different extent of resection. Wide resection was performed for 12 (40%), subtotal resection and adjunctive radiotherapy/radiosurgery for 12 (40%), while six @entity0 (20%) were solely treated with radiotherapy/radiosurgery. For these three groups, overall and progression-free survival rate were compared. RESULTS: The overall survival rate was 96% at 5  years and 67% at 10  years. Tumour progression-free survival (PFS) rates were 73% and 43% at 5 and 10  years, respectively. Local @entity1 progression was seen in 67% in all @entity0 , 58% in wide resection group, 67% in subtotal resection plus radiotherapy/radiosurgery group, and 75% in radiotherapy/radiosurgery group; however, this was not statistically significant (P   =   0.69). Neither the extent of resection nor @entity1 location significantly influenced overall and progression-free survival (P   >   0.05). With regard to the type of radiotherapy, @entity1 progression occurred in all lesions treated with external photon beam radiation therapy (EBRT) but only 38% of lesions treated with stereotactic radiosurgery (SRS) (P   =   0.003). CONCLUSIONS: Adjunctive radiotherapy/radiosurgery following subtotal resection showed comparable local control and survival to wide resection. SRS offered superior @entity1 control compared to EBRT.

title: The treatment outcome depending on the extent of resection in skull base and spinal XXXX .

answer: @entity2


abstract: @entity5 containing @entity4 of the large bowel form the majority of early @entity3 . Conclusive histological diagnosis of early @entity3 depends on two conditions; first, the whole lesion must be examined and second the resection margin must border on healthy tissue. The presence of certain histopathological features makes it possible to distinguish between cases with high and low risk of having lymph node @entity1 . Sixty-six @entity5 containing @entity4 are reported. They comprised 3.15% of 2,095 @entity5 removed by colonoscopic polypectomy during the same period. Five cases were lost to follow-up. Forty-nine @entity0 considered to be at low risk of having lymph node @entity1 have been treated by endoscopic polypectomy only with a rigorous follow-up regime including CEA estimation, ultrasonography and total colonoscopy at regular intervals. In none have distant @entity1 been found on follow-up examinations at a mean duration of 3 years. Two of these cases have developed a metachronous @entity3 and 15 (30.5%) have metachronous @entity5 . Two low risk @entity0 with no @entity2 found in the operative specimen have undergone major surgical resection. Ten high risk cases have been referred for major surgery and lymph node @entity1 have been found in four (40%). The need for careful histological examination for lymphatic and veinous invasion is stressed by the presence of this finding in all four high risk @entity0 with involved lymph nodes.

title: Large bowel XXXX containing @entity4 --a diagnostic and therapeutic approach.

answer: @entity5


abstract: @entity5 containing @entity4 of the large bowel form the majority of early @entity3 . Conclusive histological diagnosis of early @entity3 depends on two conditions; first, the whole lesion must be examined and second the resection margin must border on healthy tissue. The presence of certain histopathological features makes it possible to distinguish between cases with high and low risk of having lymph node @entity1 . Sixty-six @entity5 containing @entity4 are reported. They comprised 3.15% of 2,095 @entity5 removed by colonoscopic polypectomy during the same period. Five cases were lost to follow-up. Forty-nine @entity0 considered to be at low risk of having lymph node @entity1 have been treated by endoscopic polypectomy only with a rigorous follow-up regime including CEA estimation, ultrasonography and total colonoscopy at regular intervals. In none have distant @entity1 been found on follow-up examinations at a mean duration of 3 years. Two of these cases have developed a metachronous @entity3 and 15 (30.5%) have metachronous @entity5 . Two low risk @entity0 with no @entity2 found in the operative specimen have undergone major surgical resection. Ten high risk cases have been referred for major surgery and lymph node @entity1 have been found in four (40%). The need for careful histological examination for lymphatic and veinous invasion is stressed by the presence of this finding in all four high risk @entity0 with involved lymph nodes.

title: Large bowel @entity5 containing XXXX --a diagnostic and therapeutic approach.

answer: @entity4


abstract: In recent years prescription of opioids has increased significantly. Although effective in @entity2 management, bothersome gastrointestinal adverse effects are experienced by a substantial proportion of opioid-treated @entity0 . This can lead to difficulties with therapy and subsequently inadequate @entity2 relief. Collectively referred to as opioid-induced @entity1 , these adverse effects are the result of binding of exogenous opioids to opioid receptors in the gastrointestinal tract. This leads to disturbance of three important gastrointestinal functions: motility, coordination of sphincter function and secretion. In the clinic this manifests in a wide range of symptoms such as reflux, bloating, abdominal cramping, hard, dry stools, and incomplete evacuation, although the most known adverse effect is opioid-induced @entity3 . Traditional treatment with laxatives is often insufficient, but in recent years a number of novel pharmacological approaches have been introduced. In this review the pathophysiology, symptomatology and prevalence of opioid-induced @entity1 is presented along with the benefits and caveats of a suggested consensus definition for opioid-induced @entity3 . Finally, traditional treatment is appraised and compared with the latest pharmacological developments. In conclusion, opioid antagonists restricted to the periphery show promising results, but use of different definitions and outcome measures complicate comparison. However, an international working group has recently suggested a consensus definition for opioid-induced @entity3 and relevant outcome measures have also been proposed. If investigators within this field adapt the suggested consensus and include symptoms related to dysfunction of the upper gut, it will ease comparison and be a step forward in future research.

title: Evolving paradigms in the treatment of opioid-induced XXXX .

answer: @entity1


abstract: BACKGROUND: @entity6 ( @entity6 ) is a serious complication in @entity0 with @entity1 . The benefit of chemotherapy for @entity1 @entity0 with @entity6 remains unknown. This study was conducted to elucidate the efficacy and safety of chemotherapy for advanced @entity5 ( @entity5 ) in @entity0 with @entity6 . METHODS: Newly diagnosed @entity0 with advanced (i.e. stage IIIB and IV) @entity5 with @entity6 who received systemic chemotherapy were studied. Response rates, progression-free survival (PFS), overall survival (OS), and @entity2 were retrospectively analyzed. RESULTS: In this study, 21 @entity0 who received chemotherapy plus anticoagulation therapy between December 2009 and February 2011 were included. The objective response and disease control rates within the first regimen were 14.29% (3/21) and 76.19 %(16/21), respectively. The median PFS, one-year survival rate, and median OS were 5.50 months, 33.30%, and 8.70 months, respectively. The main grade 3/4 @entity2 observed included @entity7 (28.57%), @entity3 4 (19.05%), and @entity4 2 (9.52%). Major bleeding was not observed. CONCLUSION: Chemotherapy for newly diagnosed @entity0 with advanced @entity5 and @entity6 was feasible and had acceptable @entity2 ; however, the survival of these @entity0 remained inferior to that of @entity0 without @entity6 .

title: Efficacy and safety of chemotherapy for newly diagnosed advanced XXXX with @entity6 .

answer: @entity5


abstract: BACKGROUND: @entity6 ( @entity6 ) is a serious complication in @entity0 with @entity1 . The benefit of chemotherapy for @entity1 @entity0 with @entity6 remains unknown. This study was conducted to elucidate the efficacy and safety of chemotherapy for advanced @entity5 ( @entity5 ) in @entity0 with @entity6 . METHODS: Newly diagnosed @entity0 with advanced (i.e. stage IIIB and IV) @entity5 with @entity6 who received systemic chemotherapy were studied. Response rates, progression-free survival (PFS), overall survival (OS), and @entity2 were retrospectively analyzed. RESULTS: In this study, 21 @entity0 who received chemotherapy plus anticoagulation therapy between December 2009 and February 2011 were included. The objective response and disease control rates within the first regimen were 14.29% (3/21) and 76.19 %(16/21), respectively. The median PFS, one-year survival rate, and median OS were 5.50 months, 33.30%, and 8.70 months, respectively. The main grade 3/4 @entity2 observed included @entity7 (28.57%), @entity3 4 (19.05%), and @entity4 2 (9.52%). Major bleeding was not observed. CONCLUSION: Chemotherapy for newly diagnosed @entity0 with advanced @entity5 and @entity6 was feasible and had acceptable @entity2 ; however, the survival of these @entity0 remained inferior to that of @entity0 without @entity6 .

title: Efficacy and safety of chemotherapy for newly diagnosed advanced @entity5 with XXXX .

answer: @entity6


abstract: BACKGROUND: We evaluate test for the detection of antibodies against- @entity3 by indirect immunofluorescence (Candida Spot-IF, BioM  rieux, Lyon, France and a test developed in our laboratory to detect anti-germ tube antibodies) comparatively for the serodiagnosis of @entity1 . METHODS: A total of 121 sera from 62 @entity0 were studied retrospectively. They were divided into two groups: group I included 71 sera from 28 @entity0 with @entity1 and group II, used as control, included 50 sera from 34 @entity0 with @entity1 or without evidence of @entity2 by Candida. RESULTS: Eighty-two percent of group I samples presented anti-germ tube antibodies and 57% of the @entity0 in this group were positive by the Candida Spot-IF test. Both techniques were negative in 5 @entity0 . Five @entity0 in group II showed false positive results by Candida Spot-IF and two of them presented anti-germ tube antibodies also. Both techniques presented a poor correlation (R2 = 0.159; p < 0.001). Detection of anti-germ tube antibodies showed a sensitivity of 82% and a specificity of 94% and Candida Spot-IF showed a sensitivity of 57% and a specificity of 85%. Detection of anti-germ tube antibodies in immunocompetent @entity0 showed a sensitivity of 90% but it decreased to 62% in immunocompromised @entity0 . With the Candida Spot-IF test the sensitivity was 70 and 25%, respectively. CONCLUSIONS: The detection of anti-germ tube antibodies was more sensitive and specific than detection of antibodies by the Candida Spot-IF test and it can be used for the serodiagnosis and follow up of @entity0 with @entity1 .

title: [Comparative study of 2 technics for the diagnosis of XXXX ].

answer: @entity1


abstract: Thirty-two @entity0 underwent 38 arthroplasties for advanced @entity3 and marked soft tissue losses. Seven wrists required repair or transfer of at least one tendon for rebalancing. All @entity0 were improved by the implants. Thirty-four of the 38 @entity0 were improved beyond the functional level of a painless wrist arthrodesis. Overall, there were 23 excellent, 10 good, 3 fair, and 2 poor results. The average wrist score was 90.3 points, and the average arc of motion was 38 degrees. There were three cases of migration of the third metacarpal stem and nine cases of lucency about the stems, three of which were progressive or greater than 1 mm. There were no deep @entity2 . There was one reoperation for persistent @entity1 and one for component loosening. There were no cases of implant failure. These results indicate that this total wrist arthroplasty is a safe, reproducible procedure for radiographic class III and IV @entity3 and should be considered a first line of therapy for that group.

title: Preliminary results of total wrist arthroplasty in XXXX using the Trispherical total wrist arthroplasty.

answer: @entity3


abstract: OBJECTIVE: Negative symptoms are a significant barrier to successful functional outcome and recovery in individuals with @entity2 and their management is not unproblematic. @entity7 is a @entity4 reuptake inhibitor (NRI). Previous studies regarding the useful effects of @entity7 on deficit symptoms of @entity2 have resulted in inconsistent results. The present study therefore evaluated the effectiveness of @entity7 as an adjunctive treatment in a group of @entity2 @entity0 with prominent negative symptoms. METHOD: A total of 50 male inpatients meeting diagnosis of @entity2 entered into a 12-week parallel group, double-blind study for random assignment to @entity7 (n = 25 @entity0 ) or placebo (n = 25 @entity0 ). The inclusion criterion, in addition to the diagnosis of @entity2 , was the existence of obvious negative symptoms for a duration of at least 2 years. The Scale for Assessment of Negative Symptoms (SANS) was used as the primary outcome measure. The @entity5 ( @entity5 ), Simpson Angus Scale (SAS), Hamilton Rating Scale for @entity3 (HAM-D) and Mini-Mental Status Examination (MMSE) were used for comparison of the intervening parameters in this study. RESULTS: According to the findings, 76% of @entity0 in the target group showed some positive response to @entity7 compared with 24% in the control group (p < 0.01). The mean total score of SANS in the @entity7 group decreased significantly from 79.94    1.20 to 74.23    4.07 (p < 0.0001) at the end of the study; such an improvement was not significant in the placebo group with a decrease from 80.42    2.46 to 79.08    5.83 (p < 0.29). Changes of @entity5 were insignificant in both groups. Effect size analysis for changes of SANS at the end of assessment indicated a large improvement with @entity7 (Cohen's d = 2.91). CONCLUSION: @entity7 , as an adjuvant to @entity6 , may have a helpful effect on the @entity1 of @entity2 .

title: Amelioration of @entity1 of @entity2 by XXXX reuptake inhibitor.

answer: @entity4


abstract: OBJECTIVE: Negative symptoms are a significant barrier to successful functional outcome and recovery in individuals with @entity2 and their management is not unproblematic. @entity7 is a @entity4 reuptake inhibitor (NRI). Previous studies regarding the useful effects of @entity7 on deficit symptoms of @entity2 have resulted in inconsistent results. The present study therefore evaluated the effectiveness of @entity7 as an adjunctive treatment in a group of @entity2 @entity0 with prominent negative symptoms. METHOD: A total of 50 male inpatients meeting diagnosis of @entity2 entered into a 12-week parallel group, double-blind study for random assignment to @entity7 (n = 25 @entity0 ) or placebo (n = 25 @entity0 ). The inclusion criterion, in addition to the diagnosis of @entity2 , was the existence of obvious negative symptoms for a duration of at least 2 years. The Scale for Assessment of Negative Symptoms (SANS) was used as the primary outcome measure. The @entity5 ( @entity5 ), Simpson Angus Scale (SAS), Hamilton Rating Scale for @entity3 (HAM-D) and Mini-Mental Status Examination (MMSE) were used for comparison of the intervening parameters in this study. RESULTS: According to the findings, 76% of @entity0 in the target group showed some positive response to @entity7 compared with 24% in the control group (p < 0.01). The mean total score of SANS in the @entity7 group decreased significantly from 79.94    1.20 to 74.23    4.07 (p < 0.0001) at the end of the study; such an improvement was not significant in the placebo group with a decrease from 80.42    2.46 to 79.08    5.83 (p < 0.29). Changes of @entity5 were insignificant in both groups. Effect size analysis for changes of SANS at the end of assessment indicated a large improvement with @entity7 (Cohen's d = 2.91). CONCLUSION: @entity7 , as an adjuvant to @entity6 , may have a helpful effect on the @entity1 of @entity2 .

title: Amelioration of @entity1 of XXXX by @entity4 reuptake inhibitor.

answer: @entity2


abstract: OBJECTIVE: Negative symptoms are a significant barrier to successful functional outcome and recovery in individuals with @entity2 and their management is not unproblematic. @entity7 is a @entity4 reuptake inhibitor (NRI). Previous studies regarding the useful effects of @entity7 on deficit symptoms of @entity2 have resulted in inconsistent results. The present study therefore evaluated the effectiveness of @entity7 as an adjunctive treatment in a group of @entity2 @entity0 with prominent negative symptoms. METHOD: A total of 50 male inpatients meeting diagnosis of @entity2 entered into a 12-week parallel group, double-blind study for random assignment to @entity7 (n = 25 @entity0 ) or placebo (n = 25 @entity0 ). The inclusion criterion, in addition to the diagnosis of @entity2 , was the existence of obvious negative symptoms for a duration of at least 2 years. The Scale for Assessment of Negative Symptoms (SANS) was used as the primary outcome measure. The @entity5 ( @entity5 ), Simpson Angus Scale (SAS), Hamilton Rating Scale for @entity3 (HAM-D) and Mini-Mental Status Examination (MMSE) were used for comparison of the intervening parameters in this study. RESULTS: According to the findings, 76% of @entity0 in the target group showed some positive response to @entity7 compared with 24% in the control group (p < 0.01). The mean total score of SANS in the @entity7 group decreased significantly from 79.94    1.20 to 74.23    4.07 (p < 0.0001) at the end of the study; such an improvement was not significant in the placebo group with a decrease from 80.42    2.46 to 79.08    5.83 (p < 0.29). Changes of @entity5 were insignificant in both groups. Effect size analysis for changes of SANS at the end of assessment indicated a large improvement with @entity7 (Cohen's d = 2.91). CONCLUSION: @entity7 , as an adjuvant to @entity6 , may have a helpful effect on the @entity1 of @entity2 .

title: Amelioration of XXXX of @entity2 by @entity4 reuptake inhibitor.

answer: @entity1


abstract: The passive @entity5 ( @entity2 ) was measured by the occlusion technique in 34 preterm newborn @entity0 with @entity3 . Gestational age ranged from 27 to 33 weeks. Preterm newborn @entity0 were divided into four groups on the basis of clinical criteria. Group 1 consisted of 10 @entity0 tested during the first postnatal days (1 to 3 days) while acutely ill and requiring ventilation and @entity1 therapy. After the acute phase of @entity3 , two groups were tested: group 2 consisted of nine @entity0 (5 to 22 days of age) who no longer required ventilation, and group 3 consisted of six @entity0 (7 to 28 days of age) who subsequently had @entity4 . Group 4 consisted of nine @entity0 older than 1 month of age with confirmed @entity4 . Group 1 had significantly lower @entity2 and @entity2 normalized for body weight ( @entity2 /BW) than group 2 had (P less than 0.001). In groups 3 and 4 @entity2 was significantly lower than in group 2 (P less than 0.001), as was @entity2 /BW (P less than 0.001). There was no significant difference in @entity2 and @entity2 /BW values between groups 3 and 4. This cross-sectional study in preterm @entity0 with @entity3 suggests that @entity2 may have predictive value in regard to development of @entity4 after the acute phase of @entity3 .

title: Passive compliance of total respiratory system in preterm newborn @entity0 with XXXX .

answer: @entity3


abstract: The passive @entity5 ( @entity2 ) was measured by the occlusion technique in 34 preterm newborn @entity0 with @entity3 . Gestational age ranged from 27 to 33 weeks. Preterm newborn @entity0 were divided into four groups on the basis of clinical criteria. Group 1 consisted of 10 @entity0 tested during the first postnatal days (1 to 3 days) while acutely ill and requiring ventilation and @entity1 therapy. After the acute phase of @entity3 , two groups were tested: group 2 consisted of nine @entity0 (5 to 22 days of age) who no longer required ventilation, and group 3 consisted of six @entity0 (7 to 28 days of age) who subsequently had @entity4 . Group 4 consisted of nine @entity0 older than 1 month of age with confirmed @entity4 . Group 1 had significantly lower @entity2 and @entity2 normalized for body weight ( @entity2 /BW) than group 2 had (P less than 0.001). In groups 3 and 4 @entity2 was significantly lower than in group 2 (P less than 0.001), as was @entity2 /BW (P less than 0.001). There was no significant difference in @entity2 and @entity2 /BW values between groups 3 and 4. This cross-sectional study in preterm @entity0 with @entity3 suggests that @entity2 may have predictive value in regard to development of @entity4 after the acute phase of @entity3 .

title: Passive compliance of total respiratory system in preterm newborn XXXX with @entity3 .

answer: @entity0


abstract: OBJECTIVE: To investigate the role of an abnormal @entity5 (PSA) level and abnormal findings on a digital rectal examination (DRE) in the detection of @entity2 in @entity0 in Qatar. @entity0 AND METHODS: Between June 2008 and September 2012, 651 @entity0 had a transrectal ultrasonography-guided biopsy of the prostate (TRUSBP) at our centre. The indications for a biopsy were a high PSA level (>4  ng/mL), or an abnormal DRE result. @entity0 were assessed by a thorough history, clinical examination and routine laboratory investigations. Data, including age, DRE findings, TRUS findings, total PSA level, prostate volume and the pathology results, were evaluated. RESULTS: The mean (SD) age of the 651 @entity0 was 64.1 (7.4) years. @entity2 was detected in 181 @entity0 (27.8%), @entity3 in 275 (42.2%) and @entity4 in 236 (36.4%). The sensitivity and specificity for detecting @entity2 were 93.9% and 8.5% for an abnormal PSA level (>4  ng/mL), 46.1% and 84.7% for abnormal DRE findings, and 95% and 30.2% for the two combined. Using a receiver operating characteristics curve, a PSA threshold of 7.9  ng/mL had a sensitivity of 56.6% and specificity of 52.8%. When a PSA threshold of 7.9  ng/mL was used in combination with abnormal DRE findings, the overall accuracy was 76.9%. CONCLUSION: The PSA threshold level of 7.9  ng/mL, determined by this analysis, has a higher likelihood of detecting @entity2 in @entity0 in Qatar. However, it failed to detect @entity1 in substantially many @entity0 with statistically significant disease.

title: The role of an abnormal XXXX level and an abnormal digital rectal examination in the diagnosis of @entity2 : A cross-sectional study in Qatar.

answer: @entity5


abstract: OBJECTIVE: To investigate the role of an abnormal @entity5 (PSA) level and abnormal findings on a digital rectal examination (DRE) in the detection of @entity2 in @entity0 in Qatar. @entity0 AND METHODS: Between June 2008 and September 2012, 651 @entity0 had a transrectal ultrasonography-guided biopsy of the prostate (TRUSBP) at our centre. The indications for a biopsy were a high PSA level (>4  ng/mL), or an abnormal DRE result. @entity0 were assessed by a thorough history, clinical examination and routine laboratory investigations. Data, including age, DRE findings, TRUS findings, total PSA level, prostate volume and the pathology results, were evaluated. RESULTS: The mean (SD) age of the 651 @entity0 was 64.1 (7.4) years. @entity2 was detected in 181 @entity0 (27.8%), @entity3 in 275 (42.2%) and @entity4 in 236 (36.4%). The sensitivity and specificity for detecting @entity2 were 93.9% and 8.5% for an abnormal PSA level (>4  ng/mL), 46.1% and 84.7% for abnormal DRE findings, and 95% and 30.2% for the two combined. Using a receiver operating characteristics curve, a PSA threshold of 7.9  ng/mL had a sensitivity of 56.6% and specificity of 52.8%. When a PSA threshold of 7.9  ng/mL was used in combination with abnormal DRE findings, the overall accuracy was 76.9%. CONCLUSION: The PSA threshold level of 7.9  ng/mL, determined by this analysis, has a higher likelihood of detecting @entity2 in @entity0 in Qatar. However, it failed to detect @entity1 in substantially many @entity0 with statistically significant disease.

title: The role of an abnormal @entity5 level and an abnormal digital rectal examination in the diagnosis of XXXX : A cross-sectional study in Qatar.

answer: @entity2


abstract: OBJECTIVES: To assess and compare, in a randomised clinical trial, the efficacy of @entity4 and @entity1 as medical expulsive therapy for @entity5 . @entity0 AND METHODS: In all, 128 symptomatic @entity0 with stones in the juxtavesical tract of the ureter were randomly divided into group 1 (64 @entity0 ) receiving oral @entity1 sustained-release 30  mg/day, and group 2 (64 @entity0 ) receiving @entity4 0.4  mg/day. Both groups received oral @entity2 30  mg/day for 10  days and @entity3 75  mg intramuscularly on demand. @entity0 were assessed by weekly ultrasonography with or with no abdominal computed tomography, during a follow-up of 4  weeks. The stone passage rate and time, analgesic use, hospitalisation and endoscopic interventions were evaluated. The results were analysed statistically using appropriate tests. RESULTS: The stone expulsion rate was 55% for group 1 and 80% for group 2 (P  =  0.004). The mean stone size was 8.59 and 8.85  mm in groups 1 and 2, respectively. The mean expulsion time was 23  days for group 1 and 9  days for group 2 (P  <  0.001). The mean number of @entity3 injections was 1.19 for group 1 and 0.42 for group 2 (P  <  0.001). Eleven @entity0 in group 1 vs. two in group 2 were hospitalised (P  =  0.001). Twenty-six @entity0 in group 1 and 13 in group 2 underwent ureteroscopy (P  <  0.001). CONCLUSIONS: Medical expulsive therapy with @entity4 should be considered as a first-line treatment for index cases of @entity5 with no complications. The use of @entity4 provides better stone expulsion than does @entity1 .

title: The efficacy of @entity4 vs. XXXX for the medical expulsive therapy of distal ureteric stones: A randomised clinical trial.

answer: @entity1